Principal Associate Scientist, Biology

Overview: The Research Department at Alnylam is seeking an experienced Principal Associate Scientist to join an interdisciplinary team dedicated to broadening the preclinical application of the RNAi platform and extrahepatic siRNA delivery through in vitro and in vivo mechanistic studies. The role requires strong interpersonal skills, the capacity to multi-task, and the ability to learn and master new techniques in the field of RNAi. We particularly seek someone who is detail-oriented and who will flourish in a goal-driven team environment under tight deadlines. This position is onsite and will be primarily located in Cambridge, MA. Key Responsibilities

This candidate will engage in a variety of investigative, mechanistic siRNA research efforts to evaluate RNAi compounds by applying various biochemistry and cell/molecular biology assays. Quantify siRNA/mRNA/protein using various biochemical assays. Willingness to learn and execute new techniques to support in vitro and in vivo studies. Design, troubleshoot and interpret experiments. Prepare clearly articulated experimental reports and data presentations for a variety of audiences. Qualifications

BS/MS in Biology, Cell/Molecular Biology, Biochemistry or related field with 5-7 years of work experience, preferably in an industrial setting. Proficiency in mammalian cell culture (maintenance, transfection/stable selection) and molecular biology assays for RNA/DNA/protein quantification (qPCR, Western blotting, ELISA, immunoprecipitations). Familiarity with muscle pathophysiology and/or muscle in vitro models preferred. Prior experience conducting and/or interpreting in vivo rodent studies. Excellent lab technique and ability to work independently. Strong interpersonal skills and excellent communication skills (written and oral) are required. About Alnylam

Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality. Our culture

Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others. At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients.

#J-18808-Ljbffr